Main Menu

OptiNose, Inc.

(NASDAQ GS: OPTN)

Rigrodsky Law, P.A. is investigating OptiNose, Inc. (“OptiNose”) regarding possible breaches of fiduciary duties and other violations of law related to OptiNose’s agreement to be acquired by Paratek Pharmaceuticals. Under the terms of the agreement, OptiNose shareholders will receive $9.00 per share in cash plus up to $5.00 per share in contingent value rights payable in the event that certain net revenue milestones are achieved.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 03/28/2025


* Indicates a required field.

Back to Page